Evidence map›Paper›PMID 40456879›Full record

ArticleInternational journal of obesity (2005)2025

Multi-modal neo-adjuvant anti-obesity medications may be more effective than medically supervised weight loss or GLP-1 therapy alone in preparing BMI≥70 patients for metabolic surgery.

Michael Kachmar, Florina Corpodean, Iryna Popiv, Kyle B LaPenna, Denise M Danos, Michael W Cook, Brian A Saunders, Jean J Domercant, Vance L Albaugh, Philip R Schauer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of obesity (2005), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Michael KachmarPennington Biomedical Research Center at Louisiana State University, Baton Rouge, LA, USA.ORCID 0000-0001-8959-6565
Florina CorpodeanPennington Biomedical Research Center at Louisiana State University, Baton Rouge, LA, USA.
Iryna PopivPennington Biomedical Research Center at Louisiana State University, Baton Rouge, LA, USA.
Kyle B LaPennaDepartment of Surgery, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Denise M DanosDepartment of Behavioral & Community Health, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Michael W CookDepartment of Surgery, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Brian A SaundersOur Lady of the Lake, Franciscan Missionaries of Our Lady Health System, Baton Rouge, LA, USA.
Jean J DomercantOur Lady of the Lake, Franciscan Missionaries of Our Lady Health System, Baton Rouge, LA, USA.
Vance L AlbaughPennington Biomedical Research Center at Louisiana State University, Baton Rouge, LA, USA.ORCID 0000-0002-5267-8951
Philip R SchauerPennington Biomedical Research Center at Louisiana State University, Baton Rouge, LA, USA. philip.schauer@pbrc.edu.ORCID 0000-0002-4029-7537

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesOptimizing patients with a body mass index (BMI) ≥ 70 kg/m² for metabolic surgery (MS) is challenging. However, pre-operative weight loss may be important for improving the safety of MS for these high-risk patients. Multi-modal anti-obesity medications (mmAOM) may enhance preoperative weight loss compared to non-pharmacologic medically supervised weight loss (NP-MSWL) or glucagon-like peptide-1 receptor agonist monotherapy (Mono-GLP-1) alone. SUBJECTS/

methodsThis retrospective study analyzed 113 patients with BMI ≥ 70 kg/m² at a single metabolic disease treatment institute. INTERVENTIONS/

methodsPatients were categorized into NP-MSWL (n = 13), Mono-GLP-1 (n = 54), and mmAOM (n = 46) groups. The primary outcome was mean percent total body weight loss (%TBWL). Secondary outcomes included %TBWL across time intervals (0-23, 23-51, 51-88, and 88+ weeks).

resultsThe mmAOM group achieved the highest average - 13.07% - and median (9.93% [5.57-14.29]) %TBWL; followed by Mono-GLP-1 (5.58% [0.98-10.19]); and NP-MSWL (5% [2.97-7.02]). Significant differences among groups were confirmed by Kruskal-Wallis test (p = 0.0047). The highest median %TBWL was at 51-88 weeks (10.25 [6.49-16.45]) (p = 0.0093).

conclusionsmmAOM treatment yields the highest %TBWL, especially within the first 51 weeks of preoperative preparation, demonstrating superior efficacy over Mono-GLP-1 and NP-MSWL in patients with BMI ≥ 70 kg/m². These findings suggest that incorporating mmAOM in preoperative protocols could optimize weight loss and improve surgical outcomes for high BMI patients.

Indexed as

Anti-Obesity AgentsBariatric SurgeryGlucagon-Like Peptide 1ObesityWeight LossAdultBody Mass IndexFemaleHumansMaleMiddle AgedPreoperative CareRetrospective StudiesTreatment OutcomeAnti-Obesity AgentsGlucagon-Like Peptide 1

Identifiers

PMID40456879
PMCPMC12396963

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.